About CerevanceCerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders. The company will use a new technology.
69 articles about Cerevance
Cerevance Expands Series B Financing to $65 MillionIncreases Funds to Develop Therapeutics Acting on Novel Targets for Brain Diseases
Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B financing round, adding $20 million to the $45 million that it announced in April. With this second closing, UPMC Enterprises, Casdin Capital and Dolby Family Ventures joined the company’s investor base, while Foresite Capital added to its investment made in the first closing. Cerevance’s previous closing also included GV (formerly Google Ve
Cerevance secured $45 million in a Series B financing round to support the development of its therapeutics for central nervous system diseases, including Alzheimer’s and Parkinson’s disease.
Cerevance Closes $45 Million Series B FinancingProceeds to Fund a Diverse Pipeline of Therapeutics Acting on Novel Targets for Brain Diseases
Cerevance, a private drug discovery and development company focused on brain diseases, has closed a Series B financing, bringing in $45 million from new investors including GV (formerly Google Ventures), Bill Gates and Foresite Capital, as well as all of the company’s previous investors, which include Takeda Ventures, Inc., the corporate venture arm of Takeda Pharmaceutical Company, Ltd., the Dementia Discovery Fund and Lightstone Ventures. Cere
Cerevance to Present at the BIO CEO & Investor Conference
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced the company will present at the BIO CEO & Investor Conference, taking place in New York, Feb. 10 – 11, 2020.
BioSpace Movers & Shakers, Jan. 10
1/10/2020Pharma and biotech companies bolster their executive leadership teams and boards of directors with this week's appointments.
Cerevance Appoints Clinical Development Veteran Dr. Aoife Brennan to Board of Directors
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced the appointment of Aoife Brennan, M.B., B.Ch., to its board of directors effective January 1, 2020.
Brain-disease focused Cerevance and Takeda Pharmaceutical forged a research collaboration to tackle gastrointestinal disorders that have their roots in the central nervous system.
Cerevance Enters Research Collaboration with Takeda to Advance New Treatments for Gastrointestinal Disorders
Multi-year research alliance will apply Cerevance’s NETSseq technology to GI disorders
Cerevance Initiates Phase 2 Trial of CVN424 for Parkinson’s Disease
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, announced today the initiation of a Phase 2 clinical trial of CVN424, an oral, first-in-class compound that selectively modulates a novel, non-dopaminergic target selectively expressed in an important class of neurons in the striatum.
Cerevance to Present at the 31st Annual Piper Jaffray Healthcare Conference
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced that Brad Margus, chief executive officer, will present the company’s target discovery and clinical development work during the 31st Annual Piper Jaffray Healthcare Conference taking place December 3-5, 2019 in New York, NY.
Cerevance to Present at the 2019 BIO Investor Forum
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced that Brad Margus, Chief Executive Officer, will present the company’s target discovery and clinical development work during the 2019 BIO Investor Forum taking place October 22nd-23rd, 2019 in San Francisco, CA.
Cerevance, a pharmaceutical company focusing on central nervous system diseases, has developed a new process for peering into the gene expression of specific brain cells.
BioSpace Movers and Shakers, June 7
6/7/2019Pharma and biotech companies strengthen their executive and leadership teams with new appointments.
Cerevance Appoints CNS Drug Developer James Summers, Ph.D. as Scientific Advisor
Dr. Summers to help guide Cerevance’s Drug Discovery and Development Efforts
Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424
Results Demonstrate Safety of CVN424 and Enable Initiation of Phase 2 Study in Patients
BioSpace Movers and Shakers: April 19
4/19/2019Biotech, pharma and life science companies make appointments to leadership roles, with additions at Cerevance, Obsidian, KSQ, Lygos, and more.
Cerevance Appoints Industry Veteran as Vice President of Drug Discovery
Cerevance, a clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the appointment of Roland Bürli, Ph.D. as Vice President of Drug Discovery.
BioSpace Movers and Shakers: March 8
3/8/2019Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family.
Industry Central Nervous System Specialist Lee Dawson, Ph.D. Joins Cerevance as VP of Neuroscience
Dawson to help lead the pursuit of neuronal and glial targets revealed by cell-type-specific profiling of thousands of post-mortem human brain samples
Cerevance Appoints Ted Hibben as Chief Business Officer
Cerevance today announced that it has appointed Ted Hibben as Chief Business Officer.